NEW YORK (GenomeWeb) – Second Genome today announced it has entered into a research alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC) in Ireland.

The partners said they will develop therapies to prevent and treat inflammatory bowel disease (IBD) based on the role of the microbiome. To do so, they will analyze data from patients to find new opportunities for treatment. Second Genome has developed a drug discovery platform that integrates microbiome and host biology, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.